Company / SG&A Expense
BridgeBio Pharma, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$531.2M
FY2025
5-year range
$94.4M / $531.2M
FY2021-FY2025
Trend
+83.9%
vs FY2024
Sector context
#35 of 213
Health Care
What the data says
BridgeBio Pharma, Inc.'s sg&a expense of $531M is higher than 84% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 4 consecutive years, from $94M in FY2021 to $531M in FY2025.
Based on SEC 10-K filings.
$531M in FY2025 with a 5-year CAGR of +29.5%. Top quartile in the Health Care sector.
Increased from $192M to $531M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +54.8%
- 5-Year CAGR
- +29.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 213This company $531.2M Sector average $722.3M
▼
-26.5% below sector average
Key checks
Key Insights
- BridgeBio Pharma, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +29.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 83.9% year-over-year.
- Ranks #35 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $531.2M | +83.9% |
| FY2024 | $288.9M | +50.3% |
| FY2023 | $192.2M | +34.2% |
| FY2022 | $143.2M | +51.8% |
| FY2021 | $94.4M | -35.2% |
| FY2020 | $145.7M | +54.4% |
| FY2019 | $94.4M | +116.5% |
| FY2018 | $43.6M | +227.7% |
| FY2017 | $13.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026